Reacción a "A single dose of rapamycin in mice reduces behaviours similar to those seen in the autism spectrum for a few hours"

There are numerous genetic and environmental factors involved in the onset of autism spectrum disorder (ASD), as well as in other related neurodevelopmental disorders. In the study published in the journal Nature Communications, the authors use a model of inflammation during pregnancy, commonly employed in mice to induce ASD-related symptoms in the offspring, such as stereotypical/repetitive behaviours, sensory hypersensitivity and alterations in certain neural circuits. The authors employ a multidisciplinary approach combining animal behaviour, functional magnetic resonance imaging, electrophysiology and state-of-the-art single-cell gene expression analysis techniques to investigate the neurobiological mechanisms altered in ASD, thereby providing relevant scientific insights into the field and supporting the model’s utility in research. Furthermore, they demonstrate that treatment with rapamycin—a drug widely used as an immunosuppressant to prevent rejection in organ transplants or in various cancer therapies—could be beneficial in treating some of the symptoms of ASD.

Although numerous studies have demonstrated the therapeutic benefits of rapamycin treatment in multiple animal models of ASD and other neurological disorders, the novelty of this work lies in its demonstration that acute treatment lasting just a few hours is sufficient to reverse ASD symptoms in adult individuals. The authors argue that this implies that the adult mouse brain is still capable of remodelling and is therefore likely to benefit from this and, possibly, other pharmacological therapies.

The main limitation of the study is that the therapeutic benefits of rapamycin are only temporary and lose their effectiveness over time (due to high tolerance). Although interesting and promising, these results must be treated with caution; in the authors’ own words, treatment with rapamycin is far from being applicable in humans due to its numerous side effects, as well as the aforementioned tolerance. In my opinion, it remains to be seen whether other drugs with similar mechanisms of action, but a different pharmacological and toxicological profile, might serve this purpose.

In any case, it is worth remembering that ASD and other neurodivergent conditions are not illnesses requiring a cure, and research should focus on finding therapies to treat the symptoms that are most debilitating for patients.